HHS awards $15.6M contract for ERVEBO procurement to Merck Sharp & Dohme LLC

Contract Overview

Contract Amount: $155,843,515 ($155.8M)

Contractor: Merck Sharp & Dohme LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2024-09-30

End Date: 2034-09-29

Contract Duration: 3,651 days

Daily Burn Rate: $42.7K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: ERVEBO PROCUREMENT

Place of Performance

Location: RAHWAY, UNION County, NEW JERSEY, 07065

State: New Jersey Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $155.8 million to MERCK SHARP & DOHME LLC for work described as: ERVEBO PROCUREMENT Key points: 1. Contract awarded on a sole-source basis, raising questions about potential price efficiencies. 2. Long-term contract duration of 10 years suggests a strategic, ongoing need for the product. 3. The firm-fixed-price structure provides cost certainty but may limit flexibility for the government. 4. Procurement is managed by the Office of the Assistant Secretary for Preparedness and Response (ASPR), indicating a focus on public health emergencies. 5. The contract's value is significant, reflecting the importance of the pharmaceutical product. 6. Sole-source award limits opportunities for competitive bidding and potentially higher prices.

Value Assessment

Rating: fair

Benchmarking the value of this contract is challenging without detailed cost breakdowns or comparable sole-source procurements. The $15.6 million over 10 years averages to $1.56 million annually. Given the specialized nature of pharmaceutical manufacturing for emergency preparedness, the pricing may be justified, but the lack of competition prevents a direct comparison to assess optimal value for money. Further analysis of the unit cost and production volume would be needed to definitively assess value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. This typically occurs when only one responsible source can provide the required product or service. While this ensures access to a specific, potentially critical item, it eliminates the price discovery benefits that come from a competitive bidding process. The government did not solicit offers from multiple vendors.

Taxpayer Impact: The lack of competition means taxpayers may not be receiving the lowest possible price for this procurement. Without competitive pressure, the awarded price might be higher than what could have been achieved in an open market scenario.

Public Impact

The primary beneficiaries are public health agencies and potentially the general population, who gain access to a critical pharmaceutical product for emergency response. The contract ensures the availability of ERVEBO, a treatment for Zaire ebolavirus. The geographic impact is national, supporting the U.S. government's preparedness and response capabilities. Workforce implications are likely concentrated within Merck Sharp & Dohme's pharmaceutical manufacturing facilities.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price competition, potentially leading to higher costs for taxpayers.
Long contract duration may reduce flexibility if market conditions or needs change significantly.
Lack of transparency inherent in sole-source procurements makes independent value assessment difficult.

Positive Signals

Ensures a consistent supply of a critical pharmaceutical product for public health emergencies.
Firm-fixed-price contract provides budget certainty for the government.
Award to an established manufacturer suggests reliability in production and quality.

Sector Analysis

This contract falls within the Pharmaceutical Preparation Manufacturing sector, a critical component of the broader healthcare and life sciences industry. The market for specialized emergency-use pharmaceuticals is often characterized by high R&D costs, stringent regulatory requirements, and significant government investment for preparedness. Comparable spending benchmarks are difficult to establish due to the unique nature of such products and the typical sole-source or limited-competition awards driven by national security or public health needs.

Small Business Impact

This contract does not appear to include a small business set-aside. As a sole-source award to a large pharmaceutical company, there are no direct subcontracting opportunities mandated for small businesses through this specific contract vehicle. The impact on the small business ecosystem is therefore minimal, as the primary awardee is a major corporation.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services, specifically the Office of the Assistant Secretary for Preparedness and Response (ASPR). Accountability measures are embedded in the contract's terms and conditions, including performance expectations and delivery schedules. Transparency is limited due to the sole-source nature of the award, but contract award details are publicly available. Inspector General jurisdiction would apply to any potential fraud, waste, or abuse related to the contract.

Related Government Programs

Biodefense Preparedness Programs
Strategic National Stockpile
Emergency Pharmaceutical Procurement
Antiviral Drug Development

Risk Flags

Sole-source award limits price competition.
Long contract duration may reduce flexibility.
Lack of public cost breakdown hinders value assessment.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $155.8 million to MERCK SHARP & DOHME LLC. ERVEBO PROCUREMENT

Who is the contractor on this award?

The obligated recipient is MERCK SHARP & DOHME LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $155.8 million.

What is the period of performance?

Start: 2024-09-30. End: 2034-09-29.

What is the specific nature of ERVEBO and its importance to public health preparedness?

ERVEBO (Inmazeb) is a combination of three monoclonal antibodies used for the treatment of Zaire ebolavirus disease (EVD) in adults and children. It was developed in response to the 2014-2016 Ebola epidemic in West Africa. Its importance to public health preparedness lies in providing a crucial therapeutic option to combat potential future outbreaks of this highly contagious and often fatal disease. The U.S. government, through agencies like ASPR, invests in maintaining stockpiles and ensuring access to such life-saving treatments as part of its biodefense and pandemic preparedness strategy. This contract ensures the continued availability and procurement of ERVEBO, bolstering the nation's readiness to respond to a significant public health threat.

Why was this contract awarded on a sole-source basis instead of being competed?

Sole-source awards are typically justified when only one responsible source can provide the required supplies or services. For specialized pharmaceuticals like ERVEBO, this often stems from factors such as intellectual property rights, unique manufacturing capabilities, existing government investment in development, or the need to maintain a specific, validated supply chain. In this case, Merck Sharp & Dohme LLC is the developer and manufacturer of ERVEBO. The government likely determined that Merck was the only entity capable of producing the drug to the required specifications and standards, or that initiating a competitive process would cause unacceptable delays in securing this critical medical countermeasure.

How does the firm-fixed-price contract type impact cost and flexibility?

A firm-fixed-price (FFP) contract establishes a price that is not subject to adjustment based on the contractor's cost experience in performing the work. This provides the government with significant cost certainty, as the total price is known upfront. It shifts the risk of cost overruns entirely to the contractor. For the government, this is advantageous for budgeting and financial planning. However, it can reduce flexibility. If the contractor's costs decrease significantly due to efficiencies or market changes, the government does not benefit from those savings. Conversely, if costs increase, the contractor absorbs the loss, which might incentivize them to cut corners if not properly monitored, though quality standards are paramount in pharmaceutical production.

What are the potential risks associated with a 10-year contract duration?

A 10-year contract duration for pharmaceutical procurement presents several potential risks. Firstly, technological advancements in medicine could render ERVEBO less effective or introduce superior alternatives during the contract period, making the government locked into a potentially suboptimal treatment. Secondly, the threat landscape for Ebola or other diseases could evolve, changing the strategic importance or required quantities of the drug. Thirdly, market dynamics for raw materials or manufacturing processes could shift, impacting the long-term cost-effectiveness, although the FFP structure mitigates direct cost increases for the government. Finally, a long commitment might reduce the government's agility to pivot to new strategies or suppliers if unforeseen issues arise with the current contractor or product.

What is the historical spending context for ERVEBO procurement by the U.S. government?

Historical spending data for ERVEBO procurement prior to this $15.6 million award is not readily available in the provided data. However, the development and stockpiling of medical countermeasures like ERVEBO are typically funded through specific appropriations for public health preparedness and biodefense. Agencies like ASPR and BARDA (Biomedical Advanced Research and Development Authority) have historically invested significant sums in developing and procuring treatments for emerging infectious diseases and bioterror threats. This contract represents a substantial, long-term commitment, suggesting a strategic decision to ensure a consistent supply rather than relying on ad-hoc, shorter-term procurements, which may have been the case in earlier phases of development or initial stockpiling efforts.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: 75A50124R00001

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Merck & CO., Inc.

Address: 126 E LINCOLN AVE, RAHWAY, NJ, 07065

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $173,623,737

Exercised Options: $155,843,515

Current Obligation: $155,843,515

Actual Outlays: $29,782,980

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline